90.01 0.00 (0.00%)
After hours: 4:55PM EDT
|Bid||88.49 x 1300|
|Ask||90.06 x 900|
|Day's range||87.85 - 90.11|
|52-week range||69.10 - 95.19|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||47.18|
|Earnings date||23 Jul 2020 - 27 Jul 2020|
|Forward dividend & yield||0.98 (1.11%)|
|Ex-dividend date||04 Jun 2020|
|1y target est||97.00|
Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.
Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced CE marking and regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for the Evo IQ Syringe Infusion System. The company expects hospitals in the United Kingdom, Ireland, Greece, Australia and New Zealand to be among the first to receive the new system, with additional countries to follow in a series of planned regulatory submissions.
Results published in the CHEST Journal demonstrate benefits of using dynamic measures to guide fluid therapy decisions.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced an increase in the company’s quarterly cash dividend to a rate of $0.245 per share of common stock. This represents an approximately 11% increase over the previous quarterly dividend rate of $0.22 per share. Baxter’s Board of Directors declared the dividend payable on July 1, 2020, to stockholders of record as of June 5, 2020. The indicated annual dividend rate is now $0.98 per share of common stock.
Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer. On the call this morning, we will be discussing Baxter's first quarter 2020 financial results.
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 via webcast. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:00 a.m. Eastern Time.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the virtual BofA Securities 2020 Health Care Conference via webcast on Tuesday, May 12, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:20 a.m. Eastern Time.
Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received emergency use authorization (EUA) from the U.S. FDA for the company’s Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT).
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its first-quarter 2020 financial results on Thursday, April 30, 2020, at 7:30 a.m. Central Time.
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Baxter International Inc. (NYSE:BAX), a global medical products company, today provided an update on how the company is responding to the COVID-19 epidemic that is challenging communities and healthcare systems throughout the world. The company’s support remains focused on increasing supply of its life-sustaining medicines and medical devices amidst unprecedented, rising demand; protecting employee health and safety; expanding job opportunities globally to help meet increased product demand; and providing philanthropic grants to support impacted communities.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from Federal and Illinois authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means of a virtual format only.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced its complete financial results for the fourth quarter and full year ended December 31, 2019. In addition, the company announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2019 (the Form 10-K), which includes audited restated financial statements as of December 31, 2018 and for the years ended December 31, 2018 and 2017, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (the 3Q Form 10-Q). The company has now completed its internal investigation into certain intra-company transactions that impacted its previously reported non-operating foreign exchange gains and losses as it relates to the financial statement impacts. With these filings, Baxter is now current in its SEC reporting obligations.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2019 financial results on Tuesday, March 17, 2020, at 7:30 a.m. Central Time.